Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026

Same author

Multidisciplinary Consensus Statement for Appropriate Evaluation and Workup of Sinonasal Masses.

JAMA otolaryngology-- head & neck surgery·2026

Same author

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal of managed care & specialty pharmacy·2026

Same author

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.

Nature communications·2026

Same author

Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: Jul 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors.

Jeremiah A Wala¹, Glenn J Hanna¹

¹Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 2nd Floor, Room 2-140, Boston, MA 02215, USA.

Hematology/Oncology Clinics of North America

|June 23, 2023

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy shows promise for solid tumors. Overcoming challenges like tumor barriers and immunosuppression is key to advancing CAR T-cell treatments for various cancers.

Keywords:

Antigen selection Cellular engineering Chimeric antigen receptor Clinical trials Solid tumors Tumor microenvironment

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jul 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Engineering

Background:

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized certain hematologic malignancies.
Its translation to solid tumors faces significant biological and technical hurdles.

Purpose of the Study:

To review the current landscape of CAR T-cell therapy for solid tumors.
To highlight challenges and emerging solutions in the field.
To summarize ongoing clinical trials.

Main Methods:

Literature review of CAR T-cell therapy in solid tumors.
Discussion of patient selection, clinical management, and barriers.
Overview of synthetic biology and cellular engineering advancements.
Summary of clinical trial data for various cancer types.

Main Results:

Significant challenges exist, including physical/molecular barriers, immunosuppressive tumor microenvironments, and target antigen identification.
Synthetic biology and cellular engineering offer novel strategies to enhance CAR T-cell efficacy.
Numerous clinical trials are investigating CAR T-cell therapies across diverse solid tumors.

Conclusions:

CAR T-cell therapy holds potential for solid tumors, but overcoming tumor-specific barriers is critical.
Advancements in engineering and strategic patient selection are vital for therapeutic success.
Ongoing clinical trials will provide crucial data on efficacy and safety across multiple cancer types.